Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Receivables - Other: 2020-2024

Historic Receivables - Other for Allogene Therapeutics (ALLO) over the last 4 years, with Dec 2024 value amounting to $20.8 million.

  • Allogene Therapeutics' Receivables - Other rose 5.16% to $23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.5 million, marking a year-over-year increase of 5.16%. This contributed to the annual value of $20.8 million for FY2024, which is N/A change from last year.
  • Allogene Therapeutics' Receivables - Other amounted to $20.8 million in FY2024, which was up 1,284.87% from $1.5 million recorded in FY2022.
  • In the past 5 years, Allogene Therapeutics' Receivables - Other registered a high of $20.8 million during FY2024, and its lowest value of $1.5 million during FY2022.
  • Over the past 2 years, Allogene Therapeutics' median Receivables - Other value was $11.1 million (recorded in 2022), while the average stood at $11.1 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Receivables - Other grew by 7.89% in 2021, and later plummeted by 63.41% in 2022.
  • Allogene Therapeutics' Receivables - Other (Yearly) stood at $3.8 million in 2020, then climbed by 7.89% to $4.1 million in 2021, then plummeted by 63.41% to $1.5 million in 2022, then reached $20.8 million in 2024.